

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	2478944
<b>Application Number:</b>	10551869
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	2039
<b>Title of Invention:</b>	4-(2-Phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridine derivatives as serotonin reuptake inhibitors
<b>First Named Inventor/Applicant Name:</b>	Ask Puschl
<b>Customer Number:</b>	45821
<b>Filer:</b>	Margaret M. Buck/Kathleen Andree-Cuneo
<b>Filer Authorized By:</b>	Margaret M. Buck
<b>Attorney Docket Number:</b>	433-US-PCT
<b>Receipt Date:</b>	16-NOV-2007
<b>Filing Date:</b>	31-OCT-2006
<b>Time Stamp:</b>	15:17:46
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part/.zip	Pages (if appl.)
1	Information Disclosure Statement Letter	SIDS_As_Filed.pdf	417453 e7eb94c75298657932e8ae0aa50c109 b625942	no	2

### Warnings:

Information:
--------------

2	Information Disclosure Statement (IDS) Filed	sb0008a_fill_p1_AS_FILED.pdf	323496 8091231b95dfe89560d3b7e72195d1ce49c	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
3	Information Disclosure Statement (IDS) Filed	sb0008b_fill_p2.pdf	502026 3ba50bd320961e462674465ae95d329ccc4685	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
4	Information Disclosure Statement (IDS) Filed	sb0008b_fill_p3.pdf	419944 611debc32503cd40cf83d90dcbe850219e	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
5	Foreign Reference	WO99017777A1.pdf	6563359 50d5051bb3dd2015d11392073b2550470615ff	no	202
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	WO0050380_cited_asPCT-I-B00-00108.pdf	2323399 506597e3ed43860a1f63adef999dca3270ef	no	60
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	WO04085385A2.pdf	3599511 3c214ade1521e811c689d122579ed4a105d2d578a	no	87
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	WO05000309A2.pdf	4378824 eb14dce42b96543949f122579ed4a105d2d578a	no	96
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	Buckle_et_al_JChemSoc_Perkin_Trans_1985.pdf	322024 aabb610ec02cde13461cb520074615d0bd4a151a7	no	4
<b>Warnings:</b>					
<b>Information:</b>					

10	NPL Documents	Clayden_J_et_al_Tetrahedron_Org_Chem_Series_2002.pdf	1917091 24fb8342143e240131fb4bdddcc14d2e 7642b66	no	21
<b>Warnings:</b>					

**Information:**

11	NPL Documents	Dabrowski_et_al_Tetrahedron_2005.pdf	507799 bdac2f08374ad2bc83de117e97e5624 dd57109	no	6
<b>Warnings:</b>					

**Information:**

12	NPL Documents	Hurd_et_al_JAmerChemSoc_1940.pdf	588738 2bd43cc551da57e4d3699332ac5a00 da542fc	no	11
<b>Warnings:</b>					

**Information:**

13	NPL Documents	Klnt_et_al_Drug_Discov_Today_2004.pdf	763682 cc4c27079eaef8ff05c4b14add135a5e0a 5e9494	no	6
<b>Warnings:</b>					

**Information:**

14	NPL Documents	Kunz_Renaissance_Synlett_2003.pdf	889675 01711d3d862c1323086864235219543 c3d5f430	no	12
<b>Warnings:</b>					

**Information:**

15	NPL Documents	March_J_et_al_Adv_Org_Chem_1985.pdf	1409737 d2a9e5a8777aa0c055b7d736a1e80 280de1c	no	9
<b>Warnings:</b>					

**Information:**

16	NPL Documents	Sakamuri_S_etai_BioorgMedChemLett_2001.pdf	414991 ba6dd3ee0d9344a1bc19cf45261a0d2 0ae1bb02b	no	6
<b>Warnings:</b>					

**Information:**

17	NPL Documents	Milan_MJ_2003_As_Filed.pdf	3383487 50cb9979a323d0f79b9065e05e5653ecab 012c0d2	no	162
<b>Warnings:</b>					

**Information:**

18	NPL Documents	Parham_et.al_JOrgChem_1976_AS_FIELDED.pdf	2854990 951eb0da1f167b800da5e2074312a 969cf59d	no	5
<b>Warnings:</b>					

**Information:**

19	NPL Documents	Sato_etal_Nauyn-Schem_Arch_Pharmacol_2000.pdf	649265 2a800db578ff124c32ecaf7b7103320ef 07bfed5d	no	7
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	Siemsen_P_etal_Angw_Chem_Int_Ed_2000.pdf	2742728 a23fb02ebacc232e518d3b0b542fb16 e5446f	no	26
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Silverman_RB_The_Org_Chem_of_Drug_Designand_Drug_action_1992.pdf	1445048 e669b99a0d15121c5d54bcd4720b177 e226a40	no	3
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Tamiz_AP_etal_JMedChem_2000.pdf	919856 5a1a570c19dd5d5e5a210f865a54f42e c7e34ee	no	8
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Wang_S_etal_JMedChem200.pdf	1151606 1012959a3df9-4c50-4c50-a6ae528d54ca 6ee5e0f5	no	10
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b> 38488729					
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p>					
<p><b>New Applications Under 35 U.S.C. 111</b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p>					
<p><b>National Stage of an International Application under 35 U.S.C. 371</b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					
<p><b>New International Application Filed with the USPTO as a Receiving Office</b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					